The primary objective of this review is to synthesize the extensive evidence positioning the miR-200/ZEB axis as a central node that integrates the molecular mechanisms of both targeted therapy resistance and immune evasion in NSCLC. The gene discussed is ZEB1; the disease is non-small cell lung carcinoma.